The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
about
Cytotoxic and targeted therapy for hereditary cancersGenomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyBRCA1 and BRCA2 mutations and treatment strategies for breast cancer.The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancerProfiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomeDrug therapy for hereditary cancersBRCA mutation testing in determining breast cancer therapy.Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapyTaxanes for the treatment of metastatic breast cancer.Systemic treatment for hereditary cancers: a 2012 update.Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Systemic therapy options in BRCA mutation-associated breast cancer.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.Therapies for triple negative breast cancer.BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide.Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy
P2860
Q26739366-B9D5920A-F0FA-43D4-B52F-12F1135FF387Q33827045-6EF646A3-8B88-4BEB-B142-592C3C375676Q33894431-F3CB9FDB-E720-4069-B74B-5003B2B928CDQ34102670-BAD3EA23-3248-4786-A142-65B4DD7CCD70Q34381630-38D053D7-C00B-4B18-B355-6CDD5BB633BFQ35208929-D11786E2-7AC0-4802-8E5D-EB1300ACAD3FQ35619225-9B25576A-1737-4E69-B591-1A39F83365D9Q35671356-111B365B-3824-42D4-82F4-F468DF89D90AQ36025853-D69FA9B0-3BC2-4DC0-8E4B-C245D082DBD3Q36364762-6D8121D9-A667-4146-85BB-2434F76D5F28Q36755366-98D85839-4B0B-4F9B-83D2-5836D57320ACQ36896061-FF23CF87-B9B8-465E-84A1-BF2A31E65B62Q37128739-61B7DFF4-ECB1-4C7B-AF9D-71B50FCE337EQ38025991-E170EA25-9ED9-4F5C-9E43-62AAE1B4F543Q38087850-74FB5AF1-421D-4435-815B-BAF7276B6C80Q38129725-DD7FAE65-DA51-4993-8EB5-F81FCC607FDFQ38389226-C64AC57E-7B21-4EE2-BE18-853D19F0FEA4Q38424397-0C413EC9-D71E-41FD-9EC2-FF04216EEE9BQ38617840-CB025BFF-EF7B-4175-AAA3-8CF7A0808B4FQ38727177-7BE972DC-9682-4EFA-9F0E-799D42FAB53FQ38777346-030B85F7-0989-4A34-86D5-586684ED5AA3Q42507631-6797A1BE-64CA-424E-9221-97457084C118Q47185834-0E4FBBD2-25A5-42CE-9004-EB64635491F0Q47939487-0F02F3FA-7FE1-4426-A345-7B90CD232972Q48163701-9966F476-906E-4C7E-8443-1853063CBA3DQ50912716-80D09402-3979-4619-8B1E-CB8DB609C7F0Q58003032-32D24026-3308-45C2-B7F2-A59F24BF489D
P2860
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@ast
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@en
type
label
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@ast
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@en
prefLabel
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@ast
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@en
P2093
P2860
P356
P1433
P1476
The efficacy of taxane chemoth ...... 1 and BRCA2 mutation carriers.
@en
P2093
Agnes Jager
Carolien H M van Deurzen
Elisabeth Huijskens
J Margriet Collee
Jannet Blom
John W M Martens
Marian B E Menke-Pluijmers
Marijke Bontenbal
Mieke Kriege
P2860
P304
P356
10.1002/CNCR.26351
P407
P577
2011-07-14T00:00:00Z